The European Commission granted marketing authorization for Janssen’s Darzalex (daratumumab) in combination with lenalidomide and dexamethasone for the treatment of newly diagnosed multiple myeloma patients who are ineligible for autologous stem cell transplant.
Dicerna Pharmaceuticals Inc. and Novo Nordisk A/S announced an agreement to discover and develop novel therapies for the treatment of liver-related cardio-metabolic diseases using Dicerna’s proprietary GalXC RNAi platform technology.
AstraZeneca announced new data from five additional analyses of the landmark Phase III DAPA-HF trial, which showed that Farxiga (dapagliflozin) reduced the risk of the primary composite outcome of worsening heart failure or death from cardiovascular causes versus placebo, when added to standard of care.
The U.S. Food and Drug Administration accepted for review Tricida Inc.’s New Drug Application for veverimer (TRC101) – a non-absorbed, orally administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease – under the Accelerated Approval Program.
Cellectis announced a paper published in Nature Communications that describes a proof-of-concept for rewiring the cell pathway to create highly intelligent T-cells that can recognize cancerous tumors and cause a micro secretion of therapeutic proteins onto these tumors, which ultimately reshapes the tumor microenvironment and improves the T-cells ability to fight cancer.
W2O, a leading independent provider of analytics-driven, digital-first marketing communications to the healthcare sector, acquired award-winning scientific digital creative agency Radius Digital Science.
AstraZeneca and FibroGen Inc. presented pooled efficacy and cardiovascular (CV) safety analyses from the pivotal Phase III program assessing roxadustat for the treatment of patients with anemia from chronic kidney disease (CKD).
AstraZeneca presented detailed results from the Phase III OLYMPUS and ROCKIES trials showing that roxadustat significantly increased hemoglobin levels in non-dialysis-dependent and dialysis-dependent patients with anemia from chronic kidney disease, respectively.
Veeva Systems has acquired Physicians World, a leading provider of speakers bureau services.
Klick Health revealed a number of key additions and promotions to the full-service marketing and commercialization agency’s award-winning creative team.
Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com. 
October 2019 Focus: Top 50 Company Profiles & Financials, Outcomes Creativity Index, and more!
